Welcome to our dedicated page for Moolec Science news (Ticker: MLEC), a resource for investors and traders seeking the latest updates and insights on Moolec Science stock.
Moolec Science SA reports developments tied to its molecular farming and precision fermentation platform for food ingredients, including engineered plants and microbes designed to produce scalable protein solutions. News commonly covers the GLASO1 safflower platform for gamma-linolenic acid oils, animal-protein expression in crops such as pea seeds, and pipeline categories that include alternative proteins, bioactive compounds, nutritional oils and biological inputs.
Company updates also include public-company matters such as Nasdaq listing compliance, share consolidation, capital structure actions, and accounting effects from subsidiary derecognition. The recurring themes combine technology commercialization, agricultural and processing performance, intellectual property, and governance or listing-status developments.
Moolec Science (NASDAQ:MLEC) completed its 2026 commercial planting campaign for the GLASO1 high-GLA safflower program in American Falls, Idaho, within the optimal agronomic window. Fields were planted using soil, irrigation, and seed-conditioning protocols aimed at maximizing emergence and stand establishment.
Moolec reports prior commercial GLA concentrations around 45% and has now identified 52 elite genotypes exceeding 60% GLA on average from 320 candidates, supporting its 2027 commercial expansion and future large-scale production strategy.
Moolec Science (Nasdaq: MLEC) reported that it has regained compliance with all Nasdaq Capital Market continued listing requirements related to minimum stockholders' equity within the Panel’s remediation period.
According to Moolec, unaudited stockholders' equity was approximately $15.2 million as of December 31, 2025 and $11.3 million as of March 31, 2026. These figures reflect a partial conversion of preference shares into ordinary shares valued at about $5.47 million and pro forma adjustments for a related-party credit line disbursement of roughly $0.47 million. Moolec indicates it expects to request conversion of the remaining $4.0 million preference share balance within 12 months, which it expects would further strengthen stockholders' equity.
Moolec Science (NASDAQ:MLEC) confirmed completion of the first phase of industrialization for its GLASO1 safflower platform after a 2025 campaign that exceeded internal forecasts. The company validated agronomic and processing performance and produced high-purity GLA (~45% concentration) at commercial scale, creating ready-for-delivery product and enabling expansion beyond pet food into human nutrition, supplements, and energy feedstock development. Moolec plans GLASO1 2026 sowing in early May and is selecting top safflower varieties from a 386-line germplasm library under a strategic research collaboration to support a new renewable energy feedstock business unit.
Moolec Science (NASDAQ:MLEC) announced a scientific breakthrough: successful, stable expression of bovine myoglobin in pea seeds after a 28-month sponsored research project.
Key highlights include generational stability, deployment of proprietary constructs in a new legume crop, validation of platform flexibility, and reinforcement of the company patent portfolio for scalable protein production.
Moolec Science (NASDAQ:MLEC) announced that its 2025 U.S. GLASO1 safflower campaign produced approximately 45% GLA concentration at commercial-scale crushing. The campaign covered 1,100 acres with an average yield of ~2,200 lbs/acre, a 57% year-over-year increase versus 2024.
Moolec said the results validate compatibility with existing U.S. agricultural and processing infrastructure and mark a key operational milestone toward repeatable commercial production.
Moolec Science (NASDAQ: MLEC) was granted continued listing by a Nasdaq Hearings Panel, subject to specific conditions and timelines. The Panel acknowledged bid-price compliance effective January 16, 2026, after a January 5, 2026 reverse stock split.
The Panel retained jurisdiction through May 13, 2026 and noted the company filed its Form 20-F for year-ended June 30, 2025 on December 29, 2025. Conditions include updates on derecognition by end-February 2026, pro forma financials by end-March 2026, public disclosure of compliance actions by May 13, 2026, and demonstration of full compliance by May 13, 2026.
Moolec Science (NASDAQ:MLEC) said Nasdaq Staff issued a memo recommending the Nasdaq Hearings Panel grant an exception through June 29, 2026 to regain compliance with the stockholders' equity requirement in Listing Rule 5550(b)(1), subject to disclosure conditions. The memo cites material balance-sheet improvement after Q4 2025 derecognition events.
Moolec recorded derecognition gains of approximately $91.0M, $5.2M, and $4.6M tied to loss of control of subsidiaries in December 2025 and says these items, plus intercompany liability recognition and a preference-to-ordinary conversion, substantially increased stockholders' equity.
Moolec Science S.A. (NASDAQ: MLEC) said the Nasdaq Hearings Panel granted an exception through June 29, 2026 to demonstrate compliance with the stockholders' equity requirement in Listing Rule 5550(b)(1), subject to disclosure conditions.
Moolec reported derecognition events after bankruptcy filings for certain subsidiaries that produced estimated gains of approximately $91.0 million (loss of control of Bioceres S.A.), $5.2 million (loss of control of Bioceres LLC), and $4.6 million (loss of control of Theo I SCSp). These derecognitions, intercompany eliminations and a conversion of preference shares increased the company’s stockholders' equity and, the company believes, restored Nasdaq compliance.
Moolec Science (NASDAQ:MLEC) completed a 15-for-1 share consolidation, so every 15 ordinary shares of par value US$0.10 were consolidated into 1 ordinary share with par value US$1.50.
The company said the consolidation was consummated effective as of January 5, 2026 and that the consolidation became effective on January 5, 2025 at 8:00 a.m. Eastern Time, with market quotes reflected on a consolidation-adjusted basis at the start of trading today.
Post-consolidation, issued and outstanding shares were reduced from 10,891,761 to 726,118. Shares and publicly traded warrants continue to trade under symbols MLEC and MLECW; new CUSIP numbers are G6223S125 (shares) and G6223S117 (warrants).
Moolec Science (NASDAQ:MLEC) received a Nasdaq Listing Qualifications determination letter saying it does not meet the $2.5 million minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). Management disclosed it expects to regain compliance by recognizing an estimated $105.8 million gain from derecognition of certain subsidiaries after their bankruptcy proceedings, which the company says will produce positive net income sufficient to meet Nasdaq's $500,000 net income standard. The derecognition accounting process is underway following the subsidiaries' bankruptcy filings. This announcement is made under Nasdaq Listing Rule 5810(b) to report the receipt of a non-compliance notice.